HIMSSame story, still moving the stock
Hims & Hers is back in rally mode, and the headline reason is still the same peanut butter-and-jelly combo: FDA peptide optimism. Translation? Traders are treating any hint of a softer or more favorable policy backdrop as fuel for the stock.
Why you should care
This kind of move matters because Hims has become a mood-ring stock for peptide news. When the market believes the regulatory overhang is easing, the company gets to look less like a one-trick online telehealth name and more like a platform with real growth optionality.
The catch
The market can get a little carried away here. There’s no new business model fairy dust in the headline itself — just more buying on the idea that regulators may not slam the door on the peptide opportunity.
Big picture: if you own HIMS, this is the part where you enjoy the ride but keep one hand on the seatbelt. Regulatory optimism can power a move fast — and reverse just as quickly.